Takeda launches new AtM strategy to enhance access to its life-saving medicines for patients
Takeda Pharmaceutical Company Limited announced the launch of a bold, new Access to Medicines (AtM) strategy, aimed at increasing access to its... Read More
Claris Injectables receives five 483s from US FDA for plant in Ahmedabad
Posted on31 Aug 2016
Comments0
Claris Injectables Ltd (CIL), a wholly-owned subsidiary of the Ahmedabad-based Claris Lifesciences Ltd, has received five 483s from the US Food &... Read More
Case Study: Lesson from Mylan’s Epipen Controversy
Brand: EPIPEN Description: Epinephrine autoinjector  An epinephrine autoinjector is a medical device for injecting a measured dose or doses of epinephrine... Read More
Why USFDA issued warning letter to Unimark Remedies?
The US Food and Drug Administration (USFDA) has warned Mumbai-based Unimark Remedies Ltd for violating good manufacturing practices at its two plants... Read More
Frontida BioPharm received US FDA warning letter
Posted on28 Aug 2016
Comments0
USFDA sends the warning letter to Frontida BioPharm’s two manufacturing units, due to discrepancies in records related to manufacturing practices. FDA stated... Read More
TaiGen licensing deal with Productos CientÃficos to develop & commercialise Taigexyn (nemonoxacin) in Latin America
TaiGen Biotechnology Company, Limited (TaiGen) has signed an exclusive licensing agreement with Productos CientÃficos S.A. de C.V. (PC), a leading Mexican pharmaceutical... Read More
Pfizer to acquire an antibiotics business From AstraZeneca for $725 Million
Pfizer Inc. will acquire an antibiotics business from AstraZeneca Plc for $725 million. Background about the deal: New York-based Pfizer has been looking... Read More
Take a Competency test in Clinical trial
Take a quick competency test – MCQ type self assessment test in Clinical Trial. Basic understanding of the clinical trial terminology is... Read More
Case Analysis: Pfizer’s Acquisition of Medivation for $14 billion
Pfizer will acquire biotech firm Medivation, which specialises in cancer treatments, for some US $14 billion. Pfizer’s offer for the San Francisco-based Medivation... Read More
Case Study: Curious Case of Remicade bio-pharma patent battle with Inflectra
Posted on22 Aug 2016
Tagsbiopharma patent battle, biopharmaceuticals, Celltrion, Hospira, Inflectra, Johnson & Johnson, pfizer, Remicade, Remicade biosimilar
Comments0
Biopharmaceutical: Infliximab Class: monoclonal antibody Brand Name: Remicade Marketed By: Johnson & Johnson ——————————– Biosimilar of Infliximab is Inflectra. ——————————– Infliximab (trade... Read More